From the Alumni survey conducted in October 2023, the following data are summarized:
From the academic year 2021-2022 up to academic year 2022-2023 from the Graduate Program "Heart failure - Cardio-oncology - Cardiovascular rehabilitation" have graduated in total twenty (20) students of which fourteen (14) men and six (6) women between the ages of 24 and 55.
Three (3) students continued their studies at Doctoral level.
Eight (8) publications in scientific journals:
- The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. Nikolaos Katsiadas, Andrew Xanthopoulos, Grigorios Giamouzis, Spyridon Skoularigkis, Niki Skopeliti, Evgenia Moustaferi, Ioannis Ioannidis, Sotirios Patsilinakos, Filippos Triposkiadis and John Skoularigis. Front Cardiovasc Med, 2022 Sep 29:9:984092, doi: 10.3389/fcvm.2022.984092. eCollection 2022.
IF response factor 5.28
- The Short-Term Effect of Olive Oil Extract Enriched with Hydroxytyrosol on Cardiovascular Function. Iakovis N, Ikonomidis I, Andreadou I, Xanthopoulos A, Chamaidi A, Chrysakis N, et al. J Med Food. 2023;26(12):939-42.
IF response factor 2.542
- Myocardial Recovery. Chrysakis N, Xanthopoulos A, Magouliotis D, Starling RC, Drakos SG, Triposkiadis F, et al. Diagnostics (Basel). 2023;13(8)
IF response factor 3.7
- COVID-19 and the heart. Xanthopoulos A, Bourazana A, Giamouzis G, Skoularigki E, Dimos A, Zagouras A, Papamichalis M, Leventis I, Magouliotis DE, Triposkiadis F, Skoularigis J. World J Clin Cases. 2022 Oct 6;10(28):9970-9984. doi: 10.12998/wjcc.v10.i 28.9970.
IF response factor 1.534
- Acute Myopericarditis after the Second Dose of mRNA COVID-19 Vaccine Mimicking Acute Coronary Syndrome. Pantsios C, Anyfantakis ZA, Xanthopoulos A, Leventis I, Skoularigkis S, Dimos A, Bourazana A, Papamichalis M, Giamouzis G, Triposkiadis F, Skoularigis J. Case Rep Cardiol. 2022 Aug 9; 2022: 1600734. doi: 10.1155/2022/1600734. eCollection 2022.
IF response factor 2.6
- Rationale and design of the Hellenic Registry of Clinical events and Adherence to Lipid LowerINg therapy In acute coronary syndrome (CALLINICUS-Hellas Registry). Rallidis LS, Tasoulas D, Leventis I, Malkots B, Kladou E, Zapantiotis D, Theofilatos A, Zormpas G, Kalogeras P, Betsis C, Lykoudis A, Tsamoulis D, Kalantzis C, Miliotou A, Daios S, Delakis I, Manolis G, Papathanasiou KA, Vlachopoulos C. Hellenic. J Cardiol. 2022 Jul-Aug; 66:84-86. doi: 10.1016/j.hjc.2022.05.008. Epub 2022 May 25.
IF response factor 4.1
- Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered? Rallidis LS, Tsamoulis D, Leventis I, Kalogeras P, Delakis I, Samiotis E, Kalantzis C, Malkots B, Tasoulas D, Bouratzis V, Eleutheriou D, Daios S, Potoupni V, Zervakis S, Xygka G, Miliotou A, Papathanasiou KA, Vlachopoulos C. Cardiol Pol. 2023;81(10):1012-1014. doi: 10.33963/KP.a 2023.0147. Epub 2023 Jul 4.
IF response factor 3.71
- The Prognostic Role of Spot Urinary Sodium and Chloride in a Cohort of Hospitalized Advanced Heart Failure Patients: A Pilot Study. Xanthopoulos A, Christofidis C, Pantsios C, Magouliotis D, Bourazana A, Leventis I, Skopeliti N, Skoularigki E, Briasoulis A, Giamouzis G, Triposkiadis F, Skoularigis J. Life (Basel). 2023 Mar 5;13(3):698. doi: 10.3390/life13030698.
IF response factor 3.253
(*) In accordance with the provisions of Law 4957/2022